Evidence-Based Medicine ; Humans ; Mucocutaneous Lymph Node Syndrome ; diagnosis ; therapy

A successful attempt at percutaneous transluminanl coronary angioplasty (PTCA) to relieve stenosis of the mid-portion of the left anterior descending artery was achieved in a 6-year 9-month old boy who had multiple coronary aneurysms and stenosis due to Kawasaki disease. Despite the progression of coronary stenosis he had been well except for the perfusion defect of the anterior wall of myocardium on 99mTc-MIBI SPECT with dipyridamole infusion until PTCA was carried out after 4-year 4-months of the onset of illness. The area of stenosis was 70% before PTCA and 20% after PTCA. No restenosis at the site of PTCA was observed on follow-up angiography at 26 months after PTCA. This successful attempt may indicate that this procedure should be considered early in subclinical stenosis to prevent ischemic cardiac damage.
Angioplasty, Transluminal, Percutaneous Coronary* ; Case Report ; Child ; Coronary Disease/therapy* ; Coronary Disease/etiology ; Human ; Male ; Mucocutaneous Lymph Node Syndrome/therapy* ; Mucocutaneous Lymph Node Syndrome/complications

We try to discuss the relationship between burn and Kawasaki disease (KD), and to study the diagnosis and treatment of KD in burn children. The medical records of one burn child with KD from our pediatric ward together with those of 5 burn children with KD retrieved from foreign literature were analyzed. The clinical features of KD, including bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, skin rash, cervical lymphadenopathy, changes in the distal part of extremities, were enrolled in the study. Six patients were male and younger than 5 years old, with 2 suffering from mild burn, 2 with moderate burn, and 2 with severe burn. Two days after second degree burn, all burn children had fever and skin rash with 4 or 5 clinical symptoms and signs of KD. Among them, coronary artery dilatation was found in 1 case as detected by echocardiography, positive wound culture was found in 2 cases, negative blood culture was found in 6 cases. All patients were given high-dose gamma globulin or (and) aspirin within 10 days after the first fever, followed by control and amelioration of the disease. We conclude that the pathogenesis of KD may be related with burn wound and reabsorption of edema. KD may be suspected in burn children younger than 5 years when they had fever and skin rash at the same time.
Burns ; complications ; diagnosis ; therapy ; Child, Preschool ; Humans ; Male ; Mucocutaneous Lymph Node Syndrome ; diagnosis ; etiology ; therapy

Coronary Artery Disease ; etiology ; therapy ; Humans ; Mucocutaneous Lymph Node Syndrome ; complications ; therapy

Fatal Outcome ; Female ; Humans ; Infant ; Mucocutaneous Lymph Node Syndrome ; mortality ; therapy

Kawasaki disease (KD) is characterized with acute systemic vasculitis, occurs predominantly in children between 6 months to 5 years of age. Patients with this disease recover well and the disease is self-limited in most cases. Since it can lead to devastating cardiovascular complications, KD needs special attention. Recent reports show steady increases in the prevalence of KD in both Japan and Korea. However, specific pathogens have yet to be found. Recent advances in research on KD include searches for genetic susceptibility related to KD and research on immunopathogenesis based on innate and acquired immunity. Also, search for etiopathogenesis and treatment of KD has been actively sought after using animal models. In this paper, the recent progress of research on KD was discussed.
*Genetic Predisposition to Disease ; Heart Diseases/*complications ; Humans ; Mucocutaneous Lymph Node Syndrome/*diagnosis/etiology/physiopathology/therapy

Child ; Humans ; Immunoglobulins, Intravenous ; therapeutic use ; Mucocutaneous Lymph Node Syndrome ; drug therapy ; Neutrophils

Humans ; Mucocutaneous Lymph Node Syndrome ; drug therapy ; Tumor Necrosis Factor-alpha ; antagonists & inhibitors ; Tumor Necrosis Factors

Humans ; Immunoglobulins, Intravenous/therapeutic use* ; Infant ; Mucocutaneous Lymph Node Syndrome/therapy*

Consensus ; Humans ; Immunoglobulins, Intravenous/therapeutic use* ; Mucocutaneous Lymph Node Syndrome/therapy*